A recent article by Clinical Leader, an online resource for clinical research and trials, discusses how decentralized clinical trials (DCT) are gaining acceptance. It talks about how this format offers a patient-focused approach, which, in turn means fewer dropouts.
According to the author, DCT is enabled by two components– an enriched ecosystem and an expanded reach.
The enriched ecosystem helps in making the process attainable and simple for the patients. At the same time, the expanded reach allows researchers to broaden the scope of the trial, bringing it to patients who would otherwise be too far geographically to take part.
The two components are delivered through three categories of digital trial solutions–patient-facing platforms, data collection modules, and data exchange.
Together, these allow a wider range of patients to participate in trials, and to do so easily and successfully.
This patient-centric methodology also allows the researchers to collect more meaningful data. Whilst that is a significant benefit, it is accompanied by faster and more accurate data collection, says leading clinical research organization (CRO), ObvioHealth.
According to the company, DCTs achieve a higher recruitment rate in a shorter period of time. At the same time, they offer better communication, leading to informed consent, which is consistent with what the article states.
However, DCTs also use digital health devices and remote patient monitoring (RPM) to gather real-time and real-world data, which in turn is more accurate.
The company explains that certain symptoms may be exacerbated in an unfamiliar environment, such as a clinic.
Using blood pressure as an example, the business elaborates that this data outcome might be affected by stress. However, when using RPM, the patient is in a familiar surrounding, which leads to a more realistic reading.
The company also highlights the fact that virtual data capture means fewer gaps. Automated recording, combined with reminders to the patient to record their data in a timely manner, means that there is a lower chance of patients forgetting to input their symptoms.
Additionally, these reminders also ensure that the patients maintain research protocol by taking their medicines on time.
Finally, the company explains how a more diverse patient group means that researchers get a clearer picture–one that includes people of color and ethnic minorities.
ObvioHealth further highlights how successful remote clinical trials can be by presenting a case study. In this study, using the ObvioHealth solutions, the CRO was able to recruit 400 participants across 48 states in 28 days.
Further, there was a 90% protocol compliance rate and less than 10% of the budget was spent. There was an 85% questionnaire compliance and a dropout rate of only 8%.
The company maintains that these exceptional results are brought about by how convenient DCTs can be.
ObvioHealth is a virtual research organization that provides researchers with a proprietary app and platform to make virtual trials easier, faster, and better. To learn more about the company and the solutions it offers, please visit https://www.obviohealth.com/
ObvioHealth USA, Inc.
545 West 25th Street